# AI-Assisted Antidiabetic Drug Consultation System for Glycemic Control in Type 2 Diabetes Patients Managed by Non-Specialist Physicians

Study · id `cardio:ct-nct07684690` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT07684690](<https://clinicaltrials.gov/study/NCT07684690>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT07684690

Browse, organ or system: Metabolism  
Browse, condition area: Diabetes and metabolic disease  

## In plain language

A trial with no phase registered on ClinicalTrials.gov. The registry status is not yet recruiting. It plans to enroll 400 participants.

## Technical summary

Registry record NCT07684690. Randomized; single masking; primary purpose treatment. Start 2026-07 (anticipated); primary completion 2027-11 (anticipated). Results not posted.

## Key facts

- Design: Interventional study; randomized; single masking; primary purpose treatment
- Phase: Not applicable
- Enrolled: 400 participants (planned count; ClinicalTrials.gov record NCT07684690, source copy `cardio:ctgov-nct07684690-2026-07-06`, retrieved 2026-10-26)
- Planned start: 2026-07 (anticipated) (ClinicalTrials.gov record NCT07684690, source copy `cardio:ctgov-nct07684690-2026-07-06`, retrieved 2026-10-26)
- Primary completion: 2027-11 (anticipated) (ClinicalTrials.gov record NCT07684690, source copy `cardio:ctgov-nct07684690-2026-07-06`, retrieved 2026-10-26)
- Completion: 2027-11 (anticipated) (ClinicalTrials.gov record NCT07684690, source copy `cardio:ctgov-nct07684690-2026-07-06`, retrieved 2026-10-26)
- Countries: Taiwan (ClinicalTrials.gov record NCT07684690, source copy `cardio:ctgov-nct07684690-2026-07-06`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "NOT\_YET\_RECRUITING" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct07684690-2026-07-06`, retrieved 2026-10-26)

## The registry's words

- Brief title: AI-Assisted Antidiabetic Drug Consultation System for Glycemic Control in Type 2 Diabetes Patients Managed by Non-Specialist Physicians
- Acronym: AI-ADCS
- Condition: Type 2 Diabetes Mellitus (T2DM)
- Intervention (Device): AI-assisted antidiabetic drug consultation system
- Intervention (Other): Manual antidiabetic prescribing (without AI)
- Lead sponsor: National Taiwan University Hospital
- Lead sponsor class: OTHER

## Connected pages

- Registry condition terms include this condition: Type 2 diabetes (`cardio:type-2-diabetes`)
- Registry lists this organization as the lead sponsor: National Taiwan University Hospital (`cardio:org-national-taiwan-university-hospital`)

## Provenance

Content hash: fc52a446f78ada0218b40f291d60c9273bd60fe243f3339f3ab19e4457b237e9
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
